Niagen Bioscience Inc
NAGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.22 | 0.29 | 0.17 | -0.44 |
| FCF Yield | 2.63% | 6.91% | -13.33% | -9.78% |
| EV / EBITDA | 44.71 | -19.77 | -5.96 | -8.96 |
| Quality | ||||
| ROIC | 14.53% | -15.66% | -49.57% | -65.52% |
| Gross Margin | 61.84% | 60.76% | 59.40% | 61.51% |
| Cash Conversion Ratio | 1.42 | -1.44 | 0.91 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.40% | 7.41% | 6.73% | 13.37% |
| Free Cash Flow Growth | 71.42% | 145.16% | 37.20% | -128.75% |
| Safety | ||||
| Net Debt / EBITDA | -4.54 | 6.14 | 0.96 | 0.92 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -492.24 |
| Efficiency | ||||
| Inventory Turnover | 4.14 | 2.26 | 1.99 | 1.91 |
| Cash Conversion Cycle | 34.86 | 70.65 | 105.33 | 72.97 |